U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07237100) titled 'Mirdametinib in Patients With Advanced NF1-mutant Melanoma' on Nov. 13.
Brief Summary: The goal of this clinical trial is to evaluate clinical efficacy of mirdametinib in patients with advanced NF1-mutant melanoma whose disease has progressed while on or after previous immunotherapy. The main questions this study aims to answer are:
* To evaluate the feasibility of conducting a prospective single-center clinical trial of mirdametinib in patients with advanced NF1-mutant melanoma whose disease progresses during or after PD-1 antibody-based checkpoint inhibitor therapy.
* To evaluate preliminary clinical efficacy of mirdametinib in ...